CG Oncology is first biotech IPO of 2024, raising $380m

CG Oncology has taken the ribbon for the first biotech initial public offering (IPO) of the new year and its $380 million raise – which far outstrips the proceeds forecast

CG Oncology lines up $180m IPO and a $1bn valuation

CG Oncology is the latest biotech to take a look at a share listing in the US, aiming to raise around $180 million in the process, in another sign of a possible recovery i

First launch for Daiichi Sankyo's oncolytic virus Delytact i...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer.

Daiichi Sankyo claims first okay for oncolytic virus in Japa...

Daiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval in Japan for a therapy for cancer based on a virus that selectively kills malig

Sillajen explains Pexa-Vec trial failure – it was the rescue...

Immunotherapy arms race latest: Merck buys Viralytics for $3...

Big pharma pays 160% premium for Australian biotech